Patents by Inventor Paul Blundell

Paul Blundell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tropane analogs and methods for inhibition of monoamine transport
    Patent number: 6417221
    Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7- substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: July 9, 2002
    Assignees: Organix, Inc., President and Fellows of Harvard College
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Zhengming Chen
  • Tropane analogs and methods for inhibition of monoamine transport
    Patent number: 6353105
    Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: March 5, 2002
    Assignees: Organix, Inc., President and Fellows of Harvard College
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Zhengming Chen
  • Tropane analogs and methods for inhibition of monoamine transport
    Publication number: 20020010207
    Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Application
    Filed: June 6, 2001
    Publication date: January 24, 2002
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Zhengming Chen
  • Tropane analogs and methods for inhibition of monoamine transport
    Patent number: 6291512
    Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7- substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: September 18, 2001
    Assignees: Organix, Inc., President and Fellows of Harvard College
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Zhengming Chen
  • Dopamine transporter imaging agent
    Patent number: 6171576
    Abstract: Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.
    Type: Grant
    Filed: November 3, 1995
    Date of Patent: January 9, 2001
    Assignees: Organix Inc., President & Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: Peter C. Meltzer, Bertha K. Madras, Alan Davison, Paul Blundell, Ashfaq Mahmood, Alun G. Jones
  • Tropane analogs and methods for inhibition of monoamine transport
    Patent number: 5948933
    Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: September 7, 1999
    Assignees: Organix, Inc., President and Fellows of Harvard College
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Zhengming Chen